A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies

Laura W. Goff, Mace L. Rothenberg, A. Craig Lockhart, Bruce J. Roth, Wendy L. VerMeulen, Emily Chan, Jordan D. Berlin

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Objectives: This phase I study was conducted to evaluate the combination of irinotecan, a topoisomerase I inhibitor, with epirubicin, a topoisomerase II inhibitor, when administered sequentially on a once-every-three week basis. Methods: Irinotecan was administered at doses ranging from 100 to 150 mg/m 2 intravenously over 90 minutes, 24 hours before epirubicin, in doses from 30 to 60 mg/m2, every 3 weeks. Toxicity assessments were performed weekly. Tumor evaluation by radiographic and physical examination was performed after every 3 cycles using Response Evaluation Criteria in Solid Tumors. Results: Eighteen patients with metastatic solid tumors were enrolled in this study. The maximum tolerated dose and recommended phase II dose was irinotecan 150 mg/m2 and epirubicin 30 mg/m2. Dose-limiting toxicities were primarily neutropenia. Other toxicities at this dose level were mild. Three patients with colon cancer, 1 patient with renal cell cancer and 1 patient with adenosquamous cell carcinoma of the ethmoid sinus had stable disease. No objective responses were observed. Conclusions: The maximum tolerated dose and recommended phase II dose for irinotecan and epirubicin administered 24 hours apart every 3 weeks was 150 mg/m2 and 30 mg/m2, respectively. Higher doses were limited by significant hematologic toxicity and fatigue.

Original languageEnglish
Pages (from-to)413-416
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume31
Issue number5
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Keywords

  • Epirubicin
  • Irinotecan
  • Phase I

Fingerprint Dive into the research topics of 'A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies'. Together they form a unique fingerprint.

Cite this